@article{TLCR24512,
author = {Jeffrey Ward and Daniel Morgensztern},
title = {Role of immune checkpoint blockers in patients with EGFR mutation},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {Suppl 4},
year = {2018},
keywords = {},
abstract = {Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the current standard of care for patients with advanced stage non-small cell lung cancer (NSCLC) harboring sensitizing mutations in the EGFR gene, with response rates and progression-free survival (PFS) consistently better than chemotherapy (1,2). Nevertheless, despite the high initial responses, virtually all patients develop tumor progression with a median PFS of less than 12 months with first or second generation EGFR TKIs and 18.9 months with the third generation osimertinib (3). Therefore, there is a need for new therapies with more durable responses in this population of predominantly younger patients with less exposure to tobacco smoking.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/24512}
}